HeartBeam Ranks Second Worldwide in 12-Lead ECG Innovation, Trailing Only GE Healthcare

HeartBeam, a medical-technology company developing advanced electrocardiogram solutions, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics, ranking second worldwide in 12-lead ECG innovation among 243 analyzed firms according to PatentVest's "Total Cardiac Intelligence" report. The company trails only industry giant GE Healthcare in this critical medical technology category, highlighting its growing influence in the next generation of cardiac monitoring technology.

The ranking underscores the rapid maturation of HeartBeam's proprietary synthesis-ECG system, which captures the heart's electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This technological approach allows physicians to obtain cardiologist-level ECG data from compact devices that can be used by patients or clinicians far from traditional hospital settings. By addressing one of modern medicine's most persistent challenges—delivering high-quality cardiac monitoring for arrhythmia assessment wherever patients are—HeartBeam is positioned to transform cardiac care delivery.

The company's technology platform represents a significant advancement in portable diagnostics, creating the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This innovation enables physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities, potentially redefining the future of cardiac health management. With current clearance for arrhythmia assessment and ischemia as a future goal, the technology addresses critical gaps in remote patient monitoring.

HeartBeam's intellectual property portfolio includes 13 U.S. and 4 international-issued patents related to technology enablement, providing a competitive advantage in the growing telemedicine and remote monitoring sectors. The company's recognition comes at a time when global healthcare systems increasingly prioritize decentralized care models and remote patient monitoring solutions. For more information about HeartBeam's technology and developments, visit https://ibn.fm/BEAT.

The implications of this ranking extend beyond corporate recognition to potential impacts on global healthcare delivery. As cardiovascular disease remains a leading cause of death worldwide, technologies that enable earlier detection and monitoring outside hospital settings could significantly improve patient outcomes and reduce healthcare costs. The ability to obtain professional-grade ECG data remotely addresses critical barriers to cardiac care access, particularly in rural areas, developing regions, and for patients with mobility limitations.

Forward-looking statements in the original announcement acknowledge that actual results may differ due to various factors beyond management's control, including risks detailed in the company's SEC filings available at http://IBN.fm/Disclaimer. However, the technological validation represented by this global ranking suggests HeartBeam has developed a potentially transformative approach to cardiac diagnostics that could reshape how heart conditions are monitored and managed across healthcare systems.